European Pharmacovigilance Update Still Causing Concern
This article was originally published in The Pink Sheet Daily
Executive Summary
The European pharma industry understands the need to tighten EU pharmacovigilance rules, but increased powers for a new advisory and assessment body could signal trouble ahead.
You may also be interested in...
EMA Birth Control Safety Review Shows PRAC’s Clout, Concern About Newer Products
The Pharmacovigilance Risk Assessment Committee is assessing whether use of third- and fourth-generation combined oral contraceptives should be limited to women who cannot take other birth control pills; this is the ninth group of drugs PRAC has been asked to review.
FDA Puts Several Drugs On Its “Nice” List; EMA Decides One Is “Naughty”
NPS Pharmaceuticals, GSK, Roche and Cangene receive early holiday gifts as FDA goes on an approval spree. But EMA bears more bad news for Merck’s Tredaptive.
Europeans Tighten Drug Safety By Monitoring Active Ingredients
EMA publishes a list of active ingredients that must be monitored by European Union countries as part of efforts there to improve interstate communication and drug safety.